Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology-Genomic Integration Analysis.

Natrajan R, Sailem H, Mardakheh FK, Arias Garcia M, Tape CJ, Dowsett M, Bakal C, Yuan Y.

PLoS Med. 2016 Feb 16;13(2):e1001961. doi: 10.1371/journal.pmed.1001961. eCollection 2016 Feb.

2.

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.

Liang DH, Ensor JE, Liu ZB, Patel A, Patel TA, Chang JC, Rodriguez AA.

Breast Cancer Res Treat. 2016 Jan;155(1):139-49. doi: 10.1007/s10549-015-3635-5. Epub 2015 Dec 14.

PMID:
26667234
3.

Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.

Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, Berlin A, Have CL, Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Xie H, Harding NJ, Mak DY, Chu KC, Chong LC, Sendorek DH, P'ng C, Collins CC, Squire JA, Jurisica I, Cooper C, Eeles R, Pintilie M, Dal Pra A, Davicioni E, Lam WL, Milosevic M, Neal DE, van der Kwast T, Boutros PC, Bristow RG.

Lancet Oncol. 2014 Dec;15(13):1521-32. doi: 10.1016/S1470-2045(14)71021-6. Epub 2014 Nov 13.

4.

Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Iwamoto T, Kelly C, Mizoo T, Nogami T, Motoki T, Shien T, Taira N, Hayashi N, Niikura N, Fujiwara T, Doihara H, Matsuoka J.

Clin Breast Cancer. 2016 Apr;16(2):95-100.e1. doi: 10.1016/j.clbc.2015.10.004. Epub 2015 Nov 10.

PMID:
26631838
5.

Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.

Suo C, Hrydziuszko O, Lee D, Pramana S, Saputra D, Joshi H, Calza S, Pawitan Y.

Bioinformatics. 2015 Aug 15;31(16):2607-13. doi: 10.1093/bioinformatics/btv164. Epub 2015 Mar 24.

PMID:
25810432
6.

Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer.

Ma D, Jiang YZ, Liu XY, Liu YR, Shao ZM.

Breast Cancer Res Treat. 2017 Feb;162(1):39-48. doi: 10.1007/s10549-017-4113-z. Epub 2017 Jan 16.

PMID:
28093659
7.

A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.

Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjærde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, Kristensen VN; METABRIC Group, Brenton JD, Pharoah PD, Børresen-Dale AL, Aparicio S, Caldas C.

Mol Oncol. 2015 Jan;9(1):115-27. doi: 10.1016/j.molonc.2014.07.019. Epub 2014 Aug 8.

8.

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell'Orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou C.

JAMA Oncol. 2016 Feb;2(2):217-24. doi: 10.1001/jamaoncol.2015.4377.

PMID:
26633571
9.

Lymphovascular invasion and histologic grade are associated with specific genomic profiles in invasive carcinomas of the breast.

Fidalgo F, Rodrigues TC, Pinilla M, Silva AG, Maciel Mdo S, Rosenberg C, de Andrade VP, Carraro DM, Krepischi AC.

Tumour Biol. 2015 Mar;36(3):1835-48. doi: 10.1007/s13277-014-2786-z. Epub 2014 Nov 13.

10.

TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.

Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J.

Acta Oncol. 2000;39(3):327-33.

PMID:
10987229
11.

Expression profiling of ion channel genes predicts clinical outcome in breast cancer.

Ko JH, Ko EA, Gu W, Lim I, Bang H, Zhou T.

Mol Cancer. 2013 Sep 22;12(1):106. doi: 10.1186/1476-4598-12-106.

12.

Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women.

Colak D, Nofal A, Albakheet A, Nirmal M, Jeprel H, Eldali A, Al-Tweigeri T, Tulbah A, Ajarim D, Malik OA, Inan MS, Kaya N, Park BH, Bin Amer SM.

PLoS One. 2013 May 21;8(5):e63204. doi: 10.1371/journal.pone.0063204. Print 2013.

13.

Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, Cabral C, Pawar V, Mackay A, A'Hern R, Marchiò C, Palacios J, Natrajan R, Weigelt B, Reis-Filho JS.

J Pathol. 2012 May;227(1):42-52. doi: 10.1002/path.3990. Epub 2012 Mar 21.

14.

High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.

Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP, Costa JL, Pinder SE, van de Wiel MA, Green AR, Ellis IO, Porter PL, Tavaré S, Brenton JD, Ylstra B, Caldas C.

Genome Biol. 2007;8(10):R215.

15.

Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.

Gulati S, Martinez P, Joshi T, Birkbak NJ, Santos CR, Rowan AJ, Pickering L, Gore M, Larkin J, Szallasi Z, Bates PA, Swanton C, Gerlinger M.

Eur Urol. 2014 Nov;66(5):936-48. doi: 10.1016/j.eururo.2014.06.053. Epub 2014 Jul 19.

16.

Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.

de Lange MJ, van Pelt SI, Versluis M, Jordanova ES, Kroes WG, Ruivenkamp C, van der Burg SH, Luyten GP, van Hall T, Jager MJ, van der Velden PA.

Oncotarget. 2015 Nov 10;6(35):37824-35. doi: 10.18632/oncotarget.5637.

17.

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.

Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkilä P, Aittomäki K, Blomqvist C, Loman N, Malmström P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R42. doi: 10.1186/bcr2596. Epub 2010 Jun 24.

18.

Uncovering the genomic heterogeneity of multifocal breast cancer.

Desmedt C, Fumagalli D, Pietri E, Zoppoli G, Brown D, Nik-Zainal S, Gundem G, Rothé F, Majjaj S, Garuti A, Carminati E, Loi S, Van Brussel T, Boeckx B, Maetens M, Mudie L, Vincent D, Kheddoumi N, Serra L, Massa I, Ballestrero A, Amadori D, Salgado R, de Wind A, Lambrechts D, Piccart M, Larsimont D, Campbell PJ, Sotiriou C.

J Pathol. 2015 Aug;236(4):457-66. doi: 10.1002/path.4540. Epub 2015 May 7.

19.

Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis.

Malfettone A, Saponaro C, Paradiso A, Simone G, Mangia A.

BMC Cancer. 2012 Mar 22;12:106. doi: 10.1186/1471-2407-12-106.

20.

Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data.

Haricharan S, Bainbridge MN, Scheet P, Brown PH.

Breast Cancer Res Treat. 2014 Jul;146(1):211-20. doi: 10.1007/s10549-014-2991-x. Epub 2014 May 18.

Supplemental Content

Support Center